Gilead’s Single-Tablet “Quad” Regimen for HIV Achieves a High Rate of Virologic Suppression in Phase II Study
FOSTER CITY, Calif.—-Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 and Truvada® for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® .
Read more on Business Wire via Yahoo! Finance